PEPG

PepGen Inc. (PEPG) | Rumor.io

PepGen

PEPG

Attention (50-day avg)0%

Attention rank (50-day avg)#1,844

Bullish sentiment (50-day avg)48%

Price to earnings ratio-1.22

Market capitalization179.4M

Earnings per share-1

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-89.7M

Social

What share of all stock conversation is about PEPG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 7

*$PEPG is up 18% today, potentially tapping the 200 EMA.
A major bottoming structure is in place for PepGen Inc., with accumulation zones before a projected multi-year recovery higher.
Analyst consensus is Strong Buy with an implied upside, suggesting entry at $2.00-$2.20 or confirmation above $2.50, with a near-term target of $3.00-$4.00 and maximum target of $8-$10+.

Generated by AI

Sentiment

Of the messages about PEPG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	8.25% -86.81	74.38% -8.99
Bearish	100%	100%	91.75% +86.81	25.62% +8.99

Bullish· Mar 31

PepGen Inc. ($PEPG) has potential for a significant run-up, with a possible price target of $2.00 by the end of the day.
The stock is oversold and overdone, with great upside potential, making it a good opportunity for investors.
PepGen Inc. has a strong support level at $1.50, with a possible price target of $3.00 or higher, making it a good long-term investment.

Bearish· Mar 31

PEPG's recent trial results have been disappointing, leading to a significant share price drop.
The company's cash reserves may not be enough to sustain it through a prolonged downturn, potentially leading to another funding round or reverse stock split.
PEPG's share price has fallen to a 52-week low, with some analysts predicting it could drop even further to around $0.90.

Generated by AI

Topics

Of the messages about PEPG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	80%	78.88%
Technical Analysis	—	100%	20%	4.96%
Analysts	—	0%	0%	3.59%
Controversies	—	0%	0%	1.37%
Earnings	—	0%	0%	0.63%
Macro	—	0%	0%	10.56%

Announcements· Mar 4

The FDA has placed a partial clinical hold on PepGen's Phase 2 trial for PGN-EDODM1 due to questions over preclinical pharmacology data.
The hold did not cite any issues with the blinded clinical data from the Phase 1 Freedom study, and PepGen is submitting additional analyses to address the FDA's questions.
The company expects to report data from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026 and from the 10 mg/kg cohort in the second half of 2026.

Technical Analysis· Sep 25

The chart for $PEPG has respected key support levels, with the 4.50 zone being defended and the stock launching higher to new highs.
The stock has formed a cup and handle pattern on the 5-minute chart, with a potential breakout above $6.85, which is a historic resistance level.
The stock is in a strong uptrend, with a bullish swing forecast predicting potential targets of $6.11, $6.80, and $8.16 over the next 3-7 days, based on technical indicators such as ADX, ATR, RSI, and MACD.

Generated by AI

Community

Of the messages about PEPG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	60%	70.81%	49.89%
Newcomers	0%	40%	29.19%	50.11%

Regulars· Sep 24

The announcement of PepGen's highest mean splicing correction reported in DM1 patients could be a clearing event for larger funds, given the company's large cash reserves and upcoming offering.
PepGen's recent data release has led to a strong rally, with the stock snapping back above the 0.5 Fib at $3.70 after a pullback, and is now reconsolidating above VWAP support.
PepGen's stock price has surged, rallying up to 4.33 (over 61%), with the stock now pushing into $4.84 off a clean reclaim of the 0.618 Fib ($3.59) and VWAP ($3.42), and is being watched for potential continuation.

Newcomers· Mar 31

The newcomer investors are focused on the recent stock price drop of $PEPG, with some speculating that the drop is unjustified, while others are concerned about the company's clinical trial results and the potential impact on the stock price.
Some investors are analyzing the stock's performance and market data, including the company's cash runway and the recent FDA clinical hold, to understand the underlying factors driving the stock's decline.
Newcomers are also discussing the potential for PepGen's major shareholder, RA Capital, to double down on their positions, and the possibility of a buyout or other recovery options for shareholders.

Generated by AI

News

PepGen advances DM1 trial to highest dose cohort

1mo agoInvesting.com

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

1mo agoYahoo Finance

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

BOSTON, August 06, 2026--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

1mo agoYahoo Finance

Also Discussed

Investors talking about PEPG also mention

#	Name	Attention
1	IO Biotech, Inc.IOBT	0%0
2	Lexeo Therapeutics, Inc. Common StockLXEO	0%+0
3	Acumen Pharmaceuticals, Inc.ABOS	0%new
4	Acrivon Therapeutics, Inc.ACRV	0%new
5	Maze Therapeutics, Inc.MAZE	0%0
6	Eledon Pharmaceuticals, Inc.ELDN	0%0
7	Oric Pharmaceuticals, Inc.ORIC	0%0
8	PSTX - Poseida Therapeutics, Inc.	——
9	Entrada Therapeutics, Inc.TRDA	0%new
10	Holley Inc.HLLY	0%0

PepGen Inc.

Healthcare
Biotechnology

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company’s work centers on its proprietary Enhanced Delivery Oligonucleotide platform, which is designed to improve the delivery, uptake, and activity of conjugated oligonucleotide medicines in targeted tissues. PepGen’s current pipeline includes investigational programs for conditions such as Duchenne muscular dystrophy and myotonic dystrophy type 1, with several candidates in clinical development and additional programs in earlier stages. By concentrating on genetic disorders with high unmet medical need, PepGen aims to advance precision therapeutics that address the underlying cause of disease rather than only managing symptoms. The company is headquartered in Boston, Massachusetts.

Website

Location

321 Harrison Avenue

Boston, MA, 02118

United States

Social

What share of all stock conversation is about PEPG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 7

*$PEPG is up 18% today, potentially tapping the 200 EMA.
A major bottoming structure is in place for PepGen Inc., with accumulation zones before a projected multi-year recovery higher.
Analyst consensus is Strong Buy with an implied upside, suggesting entry at $2.00-$2.20 or confirmation above $2.50, with a near-term target of $3.00-$4.00 and maximum target of $8-$10+.

Generated by AI

Sentiment

Of the messages about PEPG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	8.25% -86.81	74.38% -8.99
Bearish	100%	100%	91.75% +86.81	25.62% +8.99

Bullish· Mar 31

PepGen Inc. ($PEPG) has potential for a significant run-up, with a possible price target of $2.00 by the end of the day.
The stock is oversold and overdone, with great upside potential, making it a good opportunity for investors.
PepGen Inc. has a strong support level at $1.50, with a possible price target of $3.00 or higher, making it a good long-term investment.

Bearish· Mar 31

PEPG's recent trial results have been disappointing, leading to a significant share price drop.
The company's cash reserves may not be enough to sustain it through a prolonged downturn, potentially leading to another funding round or reverse stock split.
PEPG's share price has fallen to a 52-week low, with some analysts predicting it could drop even further to around $0.90.

Generated by AI

Topics

Of the messages about PEPG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	80%	78.88%
Technical Analysis	—	100%	20%	4.96%
Analysts	—	0%	0%	3.59%
Controversies	—	0%	0%	1.37%
Earnings	—	0%	0%	0.63%
Macro	—	0%	0%	10.56%

Announcements· Mar 4

The FDA has placed a partial clinical hold on PepGen's Phase 2 trial for PGN-EDODM1 due to questions over preclinical pharmacology data.
The hold did not cite any issues with the blinded clinical data from the Phase 1 Freedom study, and PepGen is submitting additional analyses to address the FDA's questions.
The company expects to report data from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026 and from the 10 mg/kg cohort in the second half of 2026.

Technical Analysis· Sep 25

The chart for $PEPG has respected key support levels, with the 4.50 zone being defended and the stock launching higher to new highs.
The stock has formed a cup and handle pattern on the 5-minute chart, with a potential breakout above $6.85, which is a historic resistance level.
The stock is in a strong uptrend, with a bullish swing forecast predicting potential targets of $6.11, $6.80, and $8.16 over the next 3-7 days, based on technical indicators such as ADX, ATR, RSI, and MACD.

Generated by AI

Community

Of the messages about PEPG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	60%	70.81%	49.89%
Newcomers	0%	40%	29.19%	50.11%

Regulars· Sep 24

The announcement of PepGen's highest mean splicing correction reported in DM1 patients could be a clearing event for larger funds, given the company's large cash reserves and upcoming offering.
PepGen's recent data release has led to a strong rally, with the stock snapping back above the 0.5 Fib at $3.70 after a pullback, and is now reconsolidating above VWAP support.
PepGen's stock price has surged, rallying up to 4.33 (over 61%), with the stock now pushing into $4.84 off a clean reclaim of the 0.618 Fib ($3.59) and VWAP ($3.42), and is being watched for potential continuation.

Newcomers· Mar 31

The newcomer investors are focused on the recent stock price drop of $PEPG, with some speculating that the drop is unjustified, while others are concerned about the company's clinical trial results and the potential impact on the stock price.
Some investors are analyzing the stock's performance and market data, including the company's cash runway and the recent FDA clinical hold, to understand the underlying factors driving the stock's decline.
Newcomers are also discussing the potential for PepGen's major shareholder, RA Capital, to double down on their positions, and the possibility of a buyout or other recovery options for shareholders.

Generated by AI

PepGen

Social

Aug 7

Bullish· Mar 31

Bearish· Mar 31

Announcements· Mar 4

Technical Analysis· Sep 25

Regulars· Sep 24

Newcomers· Mar 31

PepGen advances DM1 trial to highest dose cohort

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Also Discussed

PepGen Inc.

Company Information

Location

PepGen advances DM1 trial to highest dose cohort

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Also Discussed

Social

Aug 7

Bullish· Mar 31

Bearish· Mar 31

Announcements· Mar 4

Technical Analysis· Sep 25

Regulars· Sep 24

Newcomers· Mar 31